Our vision is to provide an innovative, cost effective, and efficient way to identify new active chemical starting points to feed into early drug discovery programs.
The rise of antibiotic resistance or the increase in dementia related diseases are some examples of the need for new and better medicines. Despite significant effort and enormous amounts of money being spent by Pharmaceutical companies in finding new chemical starting points (so-called hits), the chances of those hits being developed into next generation drugs still remain low. Critically, the identification and quality of the hits are essential to feed into early drug discovery programs, and thus to deliver new and better medicines to the market.
A critical aspect of the hit identification process is the quality of the library and the screening method used in order to increase the chances of finding high-quality hits to progress. The chemical space spanned for potential “drug-like” molecules is astronomic, it has been estimated to be in the order to 1062 molecules. A structurally diverse and complex compound screening collection, designed to cover a broad area of the chemical space, is of outstanding importance to increase the chances of finding new and better hits outside the limited regions covered by conventional screening libraries.
At PharmEnable we support early drug discovery programs by providing a rapid, cost efficient, and effective platform to identify new hit candidates. At PharmEnable we use our unique and diverse virtual compound library in conjunction with our computational screening programs, to identify novel active chemical starting points against the most challenging biological targets. The discovery of these initial chemical starting points could lead to the development of next-generation medicines, for example, a novel antibacterial agent or a much needed cancer treatment.
Virtual compound library
Diverse Library with broad coverage of chemical space
Novel and synthesizable compounds
Compounds with a high degree of complexity and structural diversity
Scalable and dynamic
Computational screening programs
Latest Virtual Docking for the identification of novel in silico hits
Multi-Target Screening to establish the selectivity and toxicity profiles
Machine Learning in Drug Discovery
Unlimited to any biological target
We have over 15 years experience in Diversity-Oriented Synthesis (DOS), which aims to efficiently reach and explore broad areas of chemical space. Our world leading experience in computational chemistry enables us to interrogate this repository using state-of-the-art in silico screeningprograms to identify novel starting points for targets of interest.
Dr. Hannah Sore, Chief Executive Officer
Key roles include: Business strategy and leadership, building customer relations and deal negotiator. Experience summary: Over 14 years of research expertise, which includes extensive experience within the healthcare and drug discovery sector working in biotechnology, multinational pharmaceutical companies and academia. Over 7 years consulting and business experience across healthcare sectors at Frost & Sullivan and as a founder of HFS Scientific Ltd.
Dr. Natalia Mateu, Chief Scientific Officer
Key roles include: Compound library designer, database manager and medicinal chemistry lead. Experience summary: Over 10 years of background in organic and medicinal chemistry research, including broad experience in diversity-oriented synthesis of biologically relevant compound collections, target-oriented synthesis of small molecules for drug discovery and several years of expertise in hit-to-lead generation within the pharmaceutical industry.
Prof. David Spring, Non-Executive Board and Scientific Avisor
Dave Spring is currently a Professor at the University of Cambridge within the Chemistry Department and a Fellow of Trinity College. He was awarded a Lectureship in 2006, and promoted to a Senior Lectureship in 2008, to a Readership in 2011, and to a Professorship in 2013.
He has over 180 research publications and is a world leader in the area of diversity-oriented synthesis.
Dr. Andreas Bender, Non-Executive Board and Scientific Avisor
Andreas Bender is a Lecturer in Molecular Informatics (also known as Chem(o)informatics) in the Centre for Molecular Sciences Informatics at the University of Cambridge.
In his work, he is focused on the prediction of properties of molecules; here mainly for small molecules (which could be of therapeutic interest), and primarily in the life science field.
PrecisionLife and PharmEnable partner in search for new ALS treatments
26th November 2019, Oxford and Cambridge, United Kingdom
PrecisionLife and PharmEnable have announced a new drug discovery partnership, collaborating to develop novel treatments for Amyotrophic Lateral Sclerosis (ALS). They are joined by disease researchers at the Sheffield Institute for Translational Neuroscience (SITraN) and neurology experts from Maurice Wohl Clinical Neuroscience Institute (King’s College London).
ALS is a devastating condition that causes the progressive degeneration of nerve cells that control muscle movements. Currently available treatments can help slow down disease progression and control symptoms, but there is no known cure.
PrecisionLife (formerly known as RowAnalytics), is an innovative Oxford-based AI enabled precision medicine company. It has a world-leading ‘multi-omic’ analysis platform to find and validate new disease targets and stratify patient populations at high-resolution. This scalable, hypothesis-free target validation approach enables the development of novel precision medicine treatments addressing previously unmet medical needs.
Dr Hannah Sore, CEO of PharmEnable, said: “We are delighted to announce the new partnership between PharmEnable and PrecisionLife. We are impressed with the wealth of experience, novel analytics approaches and systematic disease insights that PrecisionLife brings to target discovery and validation. Through this partnership, we will be able to develop novel treatments addressing new targets for otherwise devastating conditions.”
PharmEnable is a Cambridge-based drug discovery company, using a combination of medicinal chemistry and AI approaches to design the next generation of specific and cost-effective small molecule drugs. PharmEnable predicts novel small molecules with complex, nature-like 3D structures, and uses computational methods to find hits for disease targets in conditions such as ALS.
Dr Steve Gardner, CEO of PrecisionLife, said: “Our partnership with PharmEnable brings together evidence-led innovation in targets and small molecule leads for complex diseases. We believe that through our partnership with PharmEnable, we will be able to develop a number of effective new medicines, and we aim to create new options for patients with ALS.”
They are joined by academic partners Professor Ammar Al-Chalabi from King’s College London, and Dr Laura Ferraiuolo at the Sheffield Institute for Translational Neuroscience (SITraN), world leading experts in the neurobiology of ALS.
With this partnership, PrecisionLife and PharmEnable bring an innovative data-driven approach to drug discovery, aiming to discover a novel treatment for ALS. The partnership will expand to cover other disease areas in the future.